Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients

Table 2 Main data on invasive mycosis.

	Group A	Group B	Total
Type of mycosis
Probable	13	7	20
Documented	9	11	20
Severe neutropenia at diagnosis of IFI	17	14	31
Lymphocyte count at diagnosis of IFI
Median (× 10⁹/L)	100	200	170
Range	(0–2230)	(0–5710)	(0–5710)
IS therapy at IFI
Steroids	14	13	27
CSA or FK 506 *	8	6	14
Number of organ involved
1	17	12	29
2	3	4	7
≥ 3	2	2	4
Type of organ involvement
Lung	22	17	39
CNS	3	1	4
Skin	1	2	3
URA	2	0	2
Heart	0	2	2
Other	1	6	7
Surgery	7	7	14
Site
Lung	6	5	11
other	1	2	3
Time from diagnosis of IA to surgery
Median (days)	27	20	26
range	(16–218)	(0–81)	(0–218)

Group A comprises patients given caspofungin-based combination therapy starting within 7 days from diagnosis of IA; Group B consists of patients given caspofungin-based combination therapy starting after 7 days from diagnosis of IA.
IS, immunosuppressive drugs; IFI, invasive fungal infection; CNS, central nervous system; URA, upper respiratory airways; *with or without other IS drugs; CSA, cyclosporine-A, FK 506, tacrolimus.

ISSN: 1471-2334